Loading
Most lymphoma chemotherapy is given at the nearest hospital, but engineered T-cell treatment is only given at a small number of approved centres, and it requires living near that centre for about a month with another adult present. The travel and the accommodation are part of the decision, not an administrative detail.
**What is and is not local.** Chemotherapy, antibody treatment and radiotherapy for lymphoma are given at the local cancer unit. Engineered T-cell therapy is not: Lymphoma Action says it can only be given at approved treatment centres with the facilities and staff to administer it safely, that eligibility is decided by a national panel of clinical experts rather than locally, and that if you are eligible you might have to travel some distance for it.
**What the month afterwards requires.** Lymphoma Action sets this out plainly, and it is the part people are least prepared for. Most people stay in hospital for at least ten days after the infusion. After discharge you must stay close to the centre, usually within an hour or two's travel, for four weeks, because the serious reactions happen in that window. You must have someone with you at all times for those four weeks, and you might not be discharged from hospital at all if there is nobody who can stay with you. If you live more than an hour away you may need to arrange accommodation nearby, and the hospital team may be able to help with this.
**What else follows from the distance.** If neurotoxicity occurs, the advice is not to drive for eight weeks from the onset of symptoms. Scans to assess the response are usually done at one month and three months, and sometimes at six, which means further journeys. Around one person in five who has this treatment needs intensive care, which is the reason the proximity rule exists rather than a formality.
**What the question is.** Not whether to accept travel, but whether the arrangements that make travel possible are in place before the cells are collected: who the other adult will be for four weeks, where you will both stay, what it costs, what the hospital or a charity will contribute, and what happens to the rest of the household and to work in the meantime. Asking the clinical nurse specialist and the charity helpline before apheresis, rather than in the week of discharge, is what makes the difference.
Showing the technology this term belongs to: CAR-T cell therapy.
Shares Transplant or CAR-T at second line in diffuse large B-cell lymphoma, Relapsed and refractory classical Hodgkin lymphoma, Primary mediastinal (thymic) large B-cell lymphoma, Follicular lymphoma.
Shares Financial toxicity and financial navigation, Financial toxicity, Follicular lymphoma, Mantle cell lymphoma.
Shares Transplant or CAR-T at second line in diffuse large B-cell lymphoma, The CAR-T pathway in lymphoma: referral, apheresis, bridging and the waiting, Primary mediastinal (thymic) large B-cell lymphoma, CAR-T cell therapy.
Shares Transplant or CAR-T at second line in diffuse large B-cell lymphoma, The CAR-T pathway in lymphoma: referral, apheresis, bridging and the waiting, CAR-T cell therapy, Non-Hodgkin lymphoma (all types).
Shares The CAR-T pathway in lymphoma: referral, apheresis, bridging and the waiting, ICANS (neurotoxicity), Primary mediastinal (thymic) large B-cell lymphoma, Follicular lymphoma.
Shares Follicular lymphoma, Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma.
Shares Primary mediastinal (thymic) large B-cell lymphoma, Follicular lymphoma, Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma.
Shares Follicular lymphoma, Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma.